Compare HXL & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HXL | TGTX |
|---|---|---|
| Founded | 1946 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 7.9B |
| IPO Year | 1994 | 2008 |
| Metric | HXL | TGTX |
|---|---|---|
| Price | $90.65 | $54.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $88.30 | $49.80 |
| AVG Volume (30 Days) | 627.6K | ★ 1.8M |
| Earning Date | 04-22-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | N/A | ★ 0.17 |
| Revenue | ★ $1,893,900,000.00 | $2,785,000.00 |
| Revenue This Year | $10.09 | $49.08 |
| Revenue Next Year | $12.33 | $26.69 |
| P/E Ratio | ★ N/A | $326.94 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $60.26 | $26.76 |
| 52 Week High | $111.74 | $59.30 |
| Indicator | HXL | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.09 | 59.68 |
| Support Level | $88.83 | $51.51 |
| Resistance Level | $92.59 | $58.04 |
| Average True Range (ATR) | 2.24 | 2.70 |
| MACD | -0.30 | 0.29 |
| Stochastic Oscillator | 10.28 | 78.59 |
Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use primarily in the commercial aerospace and defense markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engine nacelles, and other structures and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (40% of 2024 sales) and Boeing (15% of 2024 sales; 25% before the pandemic) and their respective subcontractors.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.